A5081234799- Pulmonary Hypertension Research and Treatments
- Vascular Anomalies and Treatments
- Cardiovascular Issues in Pregnancy
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Heart Failure Treatment and Management
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Lymphocytic Leukemia Research
- Prostate Cancer Treatment and Research
- Cardiac Arrhythmias and Treatments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Renal Transplantation Outcomes and Treatments
- Congenital Heart Disease Studies
- Renal Diseases and Glomerulopathies
- Blood Pressure and Hypertension Studies
- Pharmaceutical studies and practices
- Organic and Inorganic Chemical Reactions
- Antiplatelet Therapy and Cardiovascular Diseases
- Patient Satisfaction in Healthcare
- Patient-Provider Communication in Healthcare
- Cardiac and Coronary Surgery Techniques
- Antimicrobial Resistance in Staphylococcus
- Cardiac Valve Diseases and Treatments
- Phosphodiesterase function and regulation
- Chronic Myeloid Leukemia Treatments
United Therapeutics (United States)
2019-2024
Triangle
2021-2024
University of North Carolina at Chapel Hill
2019-2022
Tacrolimus exhibits high inter-patient pharmacokinetics (PK) variability, as well a narrow therapeutic index, and therefore requires drug monitoring. Germline mutations in cytochrome P450 isoforms 4 5 genes (CYP3A4/5) the ATP-binding cassette B1 gene (ABCB1) may contribute to interindividual tacrolimus PK which impact clinical outcomes among allogeneic hematopoietic stem cell transplantation (HSCT) patients. In this study, 252 adult patients who received for acute graft versus host disease...
Background Healthcare systems and policy makers worldwide are demonstrating interest in shared decision making, which requires patient activation. Patient activation can be measured using a validated tool called the measure-10. First cycle comprehensive chemotherapy consultation services (3CS) is provided by an oncology pharmacy team member during encounter at beginning of patient's treatment for cancer. Methods This was single center, prospective, non-randomized, observational clinical...
Right heart (RH) structure and function are major determinants of symptoms prognosis in pulmonary arterial hypertension (PAH). RH imaging provides detailed information, but evidence guidelines on the use treatment decisions limited. We conducted a Delphi study to gather expert opinion role decision-making for escalation PAH. A panel 17 physicians with expertise PAH used three surveys modified process reach consensus Survey 1 open-ended questions information. 2 contained Likert scale other...
Abstract Background Pulmonary hypertension due to interstitial lung disease (PH-ILD) is associated with high rates of respiratory failure and death. Healthcare resource utilization (HCRU) cost data are needed characterize PH-ILD burden. Methods A retrospective cohort analysis the Truven Health MarketScan ® Commercial Claims Encounters Database Medicare Supplemental between June 2015 2019 was conducted. Patients ILD were identified indexed based on their first claim a PH diagnosis. required...
Abstract Background Current clinical guidelines support use of parenteral prostacyclin therapy for patients with pulmonary arterial hypertension (PAH) at intermediate risk. The objective this study was to assess among risk according the Comparative, Prospective Registry Newly Initiated Therapies Pulmonary Hypertension (COMPERA) 2.0 four-strata assessment model. Methods This a retrospective chart review and cross-sectional online survey healthcare professionals (HCPs). Included were...
Mortality in pulmonary arterial hypertension (PAH) remains high and referral to palliative or supportive care (P/SC) specialist services is recommended when appropriate. However, access P/SC frequently a challenge for patients with noncancer diagnosis few living PAH report involvement their care. A modified Delphi process of three questionnaires completed by multidisciplinary panel (N = 15) was used develop expert consensus statements regarding the use support PAH. Panelists rated agreement...
Real-world dosing and titration of parenteral (subcutaneous, SC; intravenous, IV) prostacyclin, a mainstay pulmonary arterial hypertension (PAH) treatment, is not always consistent with prescribing information or randomized trials has yet to be adequately characterized. The current study describes real-world outpatient patterns over time, in PAH patients initiated on SC IV treprostinil. A longitudinal, cross-sectional analysis medication shipment records from US specialty pharmacy services...
Abstract Background The Remunity Pump for Remodulin (treprostinil) Injection is an infusion system indicated use with subcutaneous treprostinil. Objective objective was to assess the stability of diluted treprostinil sodium stored in pump cassettes. Methods Treprostinil’s chemical and physical were assessed over a 76-hour period at 40 degrees Celsius 75% relative humidity after dilution 0.01 mg/mL sterile water injection 0.9% chloride. Analyses conducted via visual inspection, pH...
Abstract The objective of this analysis was to compare clinician‐based and formally calculated risk assessments by REVEAL Lite 2 COMPERA 2.0 characterize parenteral prostacyclin utilization within 90 days baseline in high‐risk patients. A multisite, double‐blind, retrospective chart review patients with pulmonary arterial hypertension (PAH) conducted an index period January 2014–March 2017. Patients were categorized into the “any PAH medication” or “prostacyclin‐enriched” cohort based on...
Background: Tyrosine kinase inhibitors (TKIs) are the front-line therapy for chronic myeloid leukemia (CML), where phase 3 clinical trials have demonstrated their safety and efficacy. However, trial patients may not be representative of real-world (RWPs). Objective: To evaluate RWP factors associated with effectiveness in CML treated TKIs. Methods: Patients at least 30 days imatinib, dasatinib, nilotinib, or bosutinib between 2014 2018 were included. stratified into categories based on...
Abstract Background Post-hoc analyses of the FREEDOM-EV study demonstrated that addition oral treprostinil (ORE) to background monotherapy improves risk in patients with pulmonary arterial hypertension (PAH). Evidence is needed understand incremental effect ORE added dual therapy an endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5)/soluble guanylate cyclase stimulator (sGC). Purpose To describe longitudinal changes REVEAL Lite 2 COMPERA 2.0 status initiating on...
Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with clonal expansion of small lymphocytes. Ibrutinib, an irreversible inhibitor Bruton tyrosine kinase (BTK), first-line treatment option, and recent data suggest that strict adherence directly related to clinical outcomes.The primary objective this study was quantify ibrutinib rates in real-world patients CLL on ibrutinib; secondary outcomes included progression-free survival overall survival.This retrospective subjects who were...
Abstract Background Pulmonary arterial hypertension (PAH) is characterized by an increase in pulmonary vascular resistance, leading to increased afterload and right-sided heart failure. It important routinely assess disease progression treatment response, with echocardiography increasingly recognized component of risk assessment. Parenteral prostacyclin therapy has been shown be associated improvements cardiac structure function, which are prognostic PAH. Purpose To describe changes...
305 Background: The Strata trial (NCT03061305) is a multi-institutional precision oncology collaboration structured as an observational protocol that aims to match patients genomically-guided therapies. Methods: Selected University of North Carolina (UNC) metastatic prostate cancer (mPC) were enrolled on this IRB-approved study. Formalin fixed paraffin-embedded primary tumor specimens, without matched germline controls, sent for targeted next generation sequencing (NGS) detect actionable...
e16582 Background: The Strata Trial (NCT03061305) is a multi-institutional precision oncology collaboration structured as an observational protocol that aims to match patients genomically guided therapies. Methods: Selected University of North Carolina (UNC) metastatic prostate cancer (mPC) were enrolled on this IRB-approved study. Formalin fixed paraffin-embedded primary tumor specimens, without matched germline controls, sent for targeted next generation sequencing (NGS) detect actionable...